Abstract: The present disclosure relates to a micron silver particle-reinforced 316L stainless steel matrix composite, including a 316L stainless steel matrix and silver particles uniformly distributed in the 316L stainless steel matrix. The silver particles have a weight 1% to 5% of the total weight of the composite; and the composite has a density of 7.9 g/cm3 to 8.2 g/cm3 and a relative density of more than 98%. The composite is prepared by the following method: mixing raw materials of a spherical silver powder and a spherical 316L stainless steel powder; subjecting a resulting mixture to mechanical ball milling to obtain a mixed powder; sieving the mixed powder and adding a resulting powder to a powder cylinder of an SLM forming machine; and charging an inert protective gas for printing to obtain the composite.

Abstract: A method for improving a monitoring capability of a borehole-surface micro-seismic monitoring system includes selecting multiple candidate points for installing surface wireless sensors to form a natural-number-coded candidate point set and combining a fixed number of candidate points randomly selected from the candidate point set with an underground installed sensor set to form a borehole-surface micro-seismic monitoring network; carrying out multiple random selections until a certain scale of borehole-surface micro-seismic monitoring network deployment plans are generated; establishing an evaluation model for a monitoring capability of each borehole-surface micro-seismic monitoring network deployment plan according to a propagation relation equation between a micro-seismic energy and a first-arrival peak amplitude of a P-wave, forming an initial population; determining an optimal borehole-surface micro-seismic monitoring network deployment plan through a genetic algorithm; and determining an optimal surface

Abstract: A coaxial powder-feeding nozzle includes a partition wall-type shell, a powder flow area, a cooling liquid flow area and a shielding gas conveying channel. A powder self-cleaning filter is on the outer side of the partition wall-type shell; the powder self-cleaning filter includes a set of powder collecting tubes on each side of the partition wall-type shell in the axial direction; each set of powder collecting tubes includes at least one powder collecting tube; under the coaction of a suction force applied by a powder collecting system and the self-weight of residual powder, a residual powder inlet of each powder collecting tube causes the residual powder on the opposite side to roll down to the bottom along the wall surface of a metal tube to be processed on the same side, and to be gathered at the front end of the residual powder inlet of the powder collecting tube.

Abstract: A timing alignment method for data acquired by monitoring units of a borehole-surface micro-seismic monitoring system includes acquiring two rock-burst waveform data segments with GPS timestamps; calculating a time difference and a number of sampling points between each pair of adjacent GPS timestamps; adding, on an equal-interval basis, a sampling time to a sampling point missing a timestamp between each pair of adjacent GPS timestamps; calculating average sampling frequencies of the two rock-burst waveform data segments, adding, on an equal-interval basis, a sampling time to a sampling point missing a timestamp except first and last GPS timestamps in each of the two data segments; obtaining sampling times of all sampling points, resampling the sampling times according to a uniform sampling frequency; calculating a rock-burst waveform data segment at a new sampling time with a linear interpolation formula, and aligning the sampling times of the two rock-burst waveform data segments.

Abstract: A coaxial powder-feeding nozzle includes a partition wall-type shell, a powder flow area, a cooling liquid flow area and a shielding gas conveying channel. A powder self-cleaning filter is on the outer side of the partition wall-type shell; the powder self-cleaning filter includes a set of powder collecting tubes on each side of the partition wall-type shell in the axial direction; each set of powder collecting tubes includes at least one powder collecting tube; under the coaction of a suction force applied by a powder collecting system and the self-weight of residual powder, a residual powder inlet of each powder collecting tube causes the residual powder on the opposite side to roll down to the bottom along the wall surface of a metal tube to be processed on the same side, and to be gathered at the front end of the residual powder inlet of the powder collecting tube.

Abstract: Lubricious thermoplastic articles are formed from thermoplastic compounds including (a) thermoplastic elastomer selected from thermoplastic polyurethane, polyether block amide, and combinations thereof; and (b) from about 5 to about 20 weight percent, by weight of the compound, of hydrophilic water-insoluble polymer selected from polyolefin-polyoxyalkylene block copolymer, crosslinked polyvinylpyrrolidone, and combinations thereof. The thermoplastic compounds are capable of providing enhanced lubricity in the thermoplastic articles without significant degradation in mechanical properties such as elongation and tensile strength, as compared to thermoplastic articles formed from the neat thermoplastic elastomer and subjected to the same heat processing history.

Abstract: The present disclosure relates to a micron silver particle-reinforced 316L stainless steel matrix composite, including a 316L stainless steel matrix and silver particles uniformly distributed in the 316L stainless steel matrix. The silver particles have a weight 1% to 5% of the total weight of the composite; and the composite has a density of 7.9 g/cm3 to 8.2 g/cm3 and a relative density of more than 98%. The composite is prepared by the following method: mixing raw materials of a spherical silver powder and a spherical 316L stainless steel powder; subjecting a resulting mixture to mechanical ball milling to obtain a mixed powder; sieving the mixed powder and adding a resulting powder to a powder cylinder of an SLM forming machine; and charging an inert protective gas for printing to obtain the composite.

Abstract: Aspects of the present invention include the production and use of chemically modified RNAi agents (e.g., shRNAs) in gene silencing applications. The chemically modified RNAi agents disclosed herein have reduced immunostimulatory activity, increased serum stability, or both, as compared to a corresponding RNAi agent not having the chemical modification. Compositions containing chemically modified RNAi agents according to aspects of the present invention (including pharmaceutical compositions) and kits containing the same are also provided.

Abstract: An anchorage device comprising a mesh substrate coupled to an implantable medical device is disclosed, where the mesh substrate has a coating comprising a polymer, and the mesh further comprises at least one active pharmaceutical ingredient. The active pharmaceutical agent is designed to elute from the mesh over time. The mesh substrate can be configured to reduce the mass of the anchorage device such that tissue in-growth and/or scar tissue formation at the treatment site is reduced. In some embodiments, the mesh substrate can be formed with a mesh having a low areal density. In some embodiments, the mesh substrate can include one or more apertures or pores to reduce the mass of the substrate.

Abstract: Aspects of the present invention include the production and use of chemically modified RNAi agents (e.g., shRNAs) in gene silencing applications. The chemically modified RNAi agents disclosed herein have reduced immunostimulatory activity, increased serum stability, or both, as compared to a corresponding RNAi agent not having the chemical modification. Compositions containing chemically modified RNAi agents according to aspects of the present invention (including pharmaceutical compositions) and kits containing the same are also provided.

Abstract: The present invention relates to compositions and methods for development of resistance-proof siRNA therapeutics for prevention and treatment of influenza viral infections. The compositions include a pharmaceutical composition comprising siRNA molecules that target conserved regions of an influenza virus gene and a pharmaceutically acceptable polymeric carrier. In one embodiment, the polymeric carrier condenses the molecules to form a nanoparticle.

Abstract: Aspects of the present invention include the production and use of chemically modified RNAi agents (e.g., shRNAs) in gene silencing applications. The chemically modified RNAi agents disclosed herein have reduced immunostimulatory activity, increased serum stability, or both, as compared to a corresponding RNAi agent not having the chemical modification. Compositions containing chemically modified RNAi agents according to aspects of the present invention (including pharmaceutical compositions) and kits containing the same are also provided.

Abstract: The present invention relates to coatings comprising polyethylene glycol and at least one polyphenolic polymer. In particular, the polyphenolic polymer could be selected from the group consisting of tyrosine-derived polyarylates, linear polyesteramides, dihydroxybenzoate polymers, and resorcinol-derived polymers. The coating of the present invention may also include a drug, such as an antibiotic. The coatings of the present invention are suitable for use as coatings for medical devices, such as orthopedic pins or stents.

Abstract: An anchorage device comprising a mesh substrate coupled to an implantable medical device is disclosed, where the mesh substrate has a coating comprising a polymer, and the mesh further comprises at least one active pharmaceutical ingredient. The active pharmaceutical agent is designed to elute from the mesh over time. The mesh substrate can be configured to reduce the mass of the anchorage device such that tissue in-growth and/or scar tissue formation at the treatment site is reduced. In some embodiments, the mesh substrate can be formed with a mesh having a low areal density. In some embodiments, the mesh substrate can include one or more apertures or pores to reduce the mass of the substrate.

Abstract: The present invention is directed to polyphenolic polymers formed from dihydroxybenzoic acid (DHB) derivatives or from resorcinol derivatives, monomers which form such polymers, blends of the polymers with drugs and/or additional polymers, as well as medical devices formed from, coated with, impregnated by or coverings made with any of the foregoing polymers (with or without drugs) or blends (with or without drugs).

Abstract: Endoprostheses are disclosed.

Abstract: The present invention relates to compositions and methods for development of resistance-proof siRNA therapeutics for prevention and treatment of influenza viral infections. The compositions include a pharmaceutical composition comprising siRNA molecules that target conserved regions of an influenza virus gene and a pharmaceutically acceptable polymeric carrier. In one embodiment, the polymeric carrier condenses the molecules to form a nanoparticle.

Abstract: The present invention relates to coatings comprising polyethylene glycol and at least one polyphenolic polymer. In particular, the polyphenolic polymer could be selected from the group consisting of tyrosine-derived polyarylates, linear polyesteramides, dihydroxybenzoate polymers, and resorcinol-derived polymers. The coating of the present invention may also include a drug, such as an antibiotic. The coatings of the present invention are suitable for use as coatings for medical devices, such as orthopedic pins or stents.

Abstract: The present invention relates to coatings comprising polyethylene glycol and at least one polyphenolic polymer. In particular, the polyphenolic polymer could be selected from the group consisting of tyrosine-derived polyarylates, linear polyesteramides, dihydroxybenzoate polymers, and resorcinol-derived polymers. The coating of the present invention may also include a drug, such as an antibiotic. The coatings of the present invention are suitable for use as coatings for medical devices, such as orthopedic pins or stents.

Abstract: Aspects of the present invention include the production and use of chemically modified RNAi agents (e.g., shRNAs) in gene silencing applications. The chemically modified RNAi agents disclosed herein have reduced immunostimulatory activity, increased serum stability, or both, as compared to a corresponding RNAi agent not having the chemical modification. Compositions containing chemically modified RNAi agents according to aspects of the present invention (including pharmaceutical compositions) and kits containing the same are also provided.